Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial

Brief description of study

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease (COVID-19). The purpose of this study is to understand if taking hydroxychloroquine (HCQ) may be used to help treat people infected with early SARS-CoV-2 infection. Currently, there are no FDA-approved treatment drugs for SARS-CoV-2 infection or COVID-19. HCQ is currently approved to treat malaria and autoimmune diseases. This study will show whether early treatment of SARS-CoV-2 infection is effective at preventing more severe illness.


Clinical Study Identifier: s20-00669
ClinicalTrials.gov Identifier: NCT04354428


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.